Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study
Nishina, Tomohiro, Fujita, Tomoko, Yoshizuka, Naoto, Sugibayashi, Ko, Murayama, Kosho, Kuboki, Yasutoshi
Published in BMJ open (21.10.2022)
Published in BMJ open (21.10.2022)
Get full text
Journal Article
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
Kondo, Shunsuke, Iwasa, Satoru, Koyama, Takafumi, Fujita, Tomoko, Sugibayashi, Ko, Murayama, Kosho, Yamamoto, Noboru
Published in International journal of clinical oncology (01.12.2022)
Published in International journal of clinical oncology (01.12.2022)
Get full text
Journal Article
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
Yoh, Kiyotaka, Hirashima, Tomonori, Saka, Hideo, Kurata, Takayasu, Ohe, Yuichiro, Hida, Toyoaki, Mellemgaard, Anders, Verheijen, Remy B., Ou, Xiaoling, Ahmed, Ghada F., Hayama, Manabu, Sugibayashi, Ko, Oxnard, Geoffrey R.
Published in Targeted oncology (01.05.2021)
Published in Targeted oncology (01.05.2021)
Get full text
Journal Article
ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy
Pacey, Simon, Chi, Kim N., Azad, Arun, Mehra, Niven, Dev, Harveer, Gleave, Martin, Planas, Jacques, Warren, Anne, Harrington, Elizabeth, Albertella, Mark, Squatrito, Massimo, Moore, Luiza, Zhou, TJ, Womersley, Lynsey, Sugibayashi, Ko, Cosulich, Sabina, de Paula, Bruno, Lukacs, Edit, Mateo, Joaquin
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
Abstract CT269: A highly sensitive and specific PARylation assay confirms significant and durable target engagement by AZD5305 in patients
Lombardi, Benedetta, Marco-Casanova, Paola, Karapetsas, Athanasios, Hornett, Mya, Lukacs, Edit, Sugibayashi, Ko, Cosulich, Sabina, Dowson, Adam, Moorthy, Ganesh, Brown, Jessica, Yap, Timothy A., Schram, Alison M., Balmana, Judith, Luen, Stephen J., Im, Seock-Ah, Sharp, Adam, Baird, Richard, Harrington, Elizabeth A., Linardopoulos, Spiros
Published in Cancer research (Chicago, Ill.) (14.04.2023)
Published in Cancer research (Chicago, Ill.) (14.04.2023)
Get full text
Journal Article